Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery

(2017) C. Gaudy-Marqueste et al.   EUROPEAN JOURNAL OF CANCER

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies

(2017) Ee Siang Choong et al.   EUROPEAN JOURNAL OF CANCER

Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma

(2017) Swathi B. Reddy et al.   JOURNAL OF IMMUNOTHERAPY

A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response

(2017) Katrien De Wolf et al.   Journal of Translational Medicine

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy

(2017) Amélie Aboudaram et al.   MELANOMA RESEARCH

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy

(2017) Jérôme Doyen et al.   JAMA Dermatology

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

(2017) Georgina V. Long et al.   JAMA Oncology

Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma

(2017) Natasha Lakin et al.   Frontiers in Oncology

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery

(2016) Jack M. Qian et al.   CANCER

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

(2016) Xiaohong Wang et al.   CANCER RESEARCH

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab

(2016) Lauren M. Kropp et al.   JOURNAL OF IMMUNOTHERAPY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

(2016) J. Naidoo et al.   Cancer Immunology Research

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

(2016) E. Liniker et al.   OncoImmunology

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

(2015) K. A. Ahmed et al.   ANNALS OF ONCOLOGY

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

(2015) Ravi A Chandra et al.   OncoImmunology

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

(2014) A. B. Sharabi et al.   Cancer Immunology Research

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

(2014) Antonio M Grimaldi et al.   OncoImmunology

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes

(2012) Stéphanie Moreau et al.   ANNALS OF SURGICAL ONCOLOGY

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER